Literature DB >> 19803001

Pharmacokinetic studies of ceftazidime in serum, bone, bile, tissue fluid and peritoneal fluid.

D H Wittmann1, H H Schassan, F Kohler, W Seibert.   

Abstract

After a single iv bolus injection of 2 g ceftazidime, concentrations were measured in serum and urine in volunteers and in serum, bone, bile and tissue fluid in patients. The serum half-life was 171 min in volunteers (n=6, average age 26 years) and 221 min in patients (n=12, average age 58 years). The peripheral volumes of distribution were also different, being 7.81 in volunteers and 11.31 in patients. Urinary recovery from the volunteers averaged 92% of the dose. Bone samples free from blood and taken from the femoral head, the pelvis or the femoral shaft contained an average of 24.1 mg ceftazidime per litre of organic bone at 30 min after injection and 19.7 mg/l at 2 h. Samples of fluid from the periprosthetic space after hip replacement contained 25.6 mg/l at 2 h and were above 8 mg/l at 10 h. Bile concentrations reached 36.4 mg/l at 90 min and were above 8 mg/l for over 8 h. Peritoneal fluid samples contained 27.6 mg/l at 1 h and 8.0 mg/l at 8 h. These concentrations are considered sufficient to treat most aerobic infections associated with surgery.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 19803001

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Penetration of cefazolin, ceftriaxone, cefoperazone, and ceftazidime into human gallbladder tissue and bile.

Authors:  S A Berger; Y Levy; A Halevy; A Gorea; R Orda
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

2.  MIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates.

Authors:  Andrei Zidaru; Brianna M Eales; Weiqun Wang; Paul R Merlau; Todd M Lasco; Amelia K Sofjan; Vincent H Tam
Journal:  J Glob Antimicrob Resist       Date:  2020-11-06       Impact factor: 4.035

3.  Further methodological improvement in antibiotic bone concentration measurements: penetration of ofloxacin into bone and cartilage.

Authors:  D H Wittmann; E Kotthaus
Journal:  Infection       Date:  1986       Impact factor: 3.553

4.  Tissue concentrations of third-generation cephalosporins (ceftazidime and ceftriaxone) in lower extremity tissues using a tourniquet.

Authors:  N Papaioannou; L Kalivas; J Kalavritinos; S Tsourvakas
Journal:  Arch Orthop Trauma Surg       Date:  1994       Impact factor: 3.067

5.  Kinetics of ceftazidime during plasmapheresis.

Authors:  F Bozkurt; P Schollmeyer; E Keller
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  The pharmacokinetic behaviour of ceftazidime in man and the relationship between serum levels and the in vitro susceptibility of clinical isolates.

Authors:  S M Harding; P B Harper
Journal:  Infection       Date:  1983       Impact factor: 3.553

Review 8.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 9.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.